Loading…
Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study
Sodium glucose cotransporter 2 (SGLT2) have proven profound positive effects in heart failure with reduced ejection fraction (HFrEF). These effects are independent from the presence of diabetes. Metabolic effects, antiinflammatory, and antifibrotic properties are discussed as underlying mechanisms....
Saved in:
Published in: | The American heart journal 2022-04, Vol.246, p.152-160 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c424t-4d71510bb8710f069dc3a061b2e12540563981b81e6860c9297b90a2fe6956323 |
---|---|
cites | cdi_FETCH-LOGICAL-c424t-4d71510bb8710f069dc3a061b2e12540563981b81e6860c9297b90a2fe6956323 |
container_end_page | 160 |
container_issue | |
container_start_page | 152 |
container_title | The American heart journal |
container_volume | 246 |
creator | von Lewinski, Dirk Tripolt, Norbert J Sourij, Harald Pferschy, Peter N Oulhaj, Abderrahim Alber, Hannes Gwechenberger, Marianne Martinek, Martin Seidl, Sebastian Moertl, Deddo Nürnberg, Michael Roithinger, Franz Xaver Steinwender, Clemens Stühlinger, Markus Zirlik, Andreas Benedikt, Martin Kolesnik, Ewald Wallner, Markus Rohrer, Ursula Manninger, Martin Scherr, Daniel |
description | Sodium glucose cotransporter 2 (SGLT2) have proven profound positive effects in heart failure with reduced ejection fraction (HFrEF). These effects are independent from the presence of diabetes. Metabolic effects, antiinflammatory, and antifibrotic properties are discussed as underlying mechanisms. Despite a strong correlation of ventricular arrhythmias with HFrEF, the impact of ertugliflozin on the ventricular arrhythmic burden has not been investigated, yet. Therefore, the Ertugliflozin to Reduce Arrhythmic burden in ICD ± CRT patientS (ERASe) trial was designed to investigate the efficacy and safety of ertugliflozin in patients with reduced and midrange ejection fraction (EF) with or without diabetes.
Within a multicentre, national, randomized, double-blind, placebo-controlled, phase 3b trial we aim to enrol a total of 402 patients across Austria. Patients with reduced or midrange EF and ICD ± CRT therapy >3 months and previous ventricular tachycardia (at least 10 documented VT episodes within the last 12 months) are randomized in a 1:1 ratio to ertugliflozin (5 mg once daily orally administered) or matching placebo. The primary endpoint of the ERASe trial is to investigate the impact of ertugliflozin on total burden of ventricular arrhythmias. Further objectives will include number of therapeutic interventions of implanted devices, atrial fibrillation and heart failure biomarkers.
The ERASe trial will be the first trial to test ertugliflozin in heart failure patients with nonpreserved ejection fraction and ongoing ICD ± CRT therapy regardless of their diabetic status. The ERASe trial may therefore extend the concept of SGLT2 inhibition to improve cardiac remodelling, including reduced arrhythmic burden.
Trial registration Identifier EudraCT Nr. 2020-002581-14 / ClinicalTrials.gov Identifier: NCT04600921 |
doi_str_mv | 10.1016/j.ahj.2022.01.008 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2621657638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870322000072</els_id><sourcerecordid>2621657638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-4d71510bb8710f069dc3a061b2e12540563981b81e6860c9297b90a2fe6956323</originalsourceid><addsrcrecordid>eNp9kMFu1DAQhi0EokvhAbggS1zKIenYTuxEnFbLApEqIZVythxnwjrKJovtVFpOfYe-IU-Cqy0cOHAajeb7f40-Ql4zyBkweTnkZjfkHDjPgeUA1ROyYlCrTKqieEpWAMCzSoE4Iy9CGNIqeSWfkzNRQlEKrlbEbH1cvo-uH-efbqJxph67xSI13u-Ocbd3lraL73Ci6dxsPlxurm_owUSHUwz0Ynu9_opZ9M6M7-ivu3u6poedCUibpqEhLt3xJXnWmzHgq8d5Tr593N5sPmdXXz41m_VVZgtexKzoFCsZtG2lGPQg684KA5K1HBkvCyilqCvWVgxlJcHWvFZtDYb3KOt04-KcXJx6D37-sWCIeu-CxXE0E85L0FxyJkslRZXQt_-gw7z4KX2XKCGFglIUiWInyvo5BI-9Pni3N_6oGegH_3rQyb9-8K-B6eQ_Zd48Ni_tHru_iT_CE_D-BGBScevQ62CTSoud82ij7mb3n_rfsaWSPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2636370534</pqid></control><display><type>article</type><title>Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>von Lewinski, Dirk ; Tripolt, Norbert J ; Sourij, Harald ; Pferschy, Peter N ; Oulhaj, Abderrahim ; Alber, Hannes ; Gwechenberger, Marianne ; Martinek, Martin ; Seidl, Sebastian ; Moertl, Deddo ; Nürnberg, Michael ; Roithinger, Franz Xaver ; Steinwender, Clemens ; Stühlinger, Markus ; Zirlik, Andreas ; Benedikt, Martin ; Kolesnik, Ewald ; Wallner, Markus ; Rohrer, Ursula ; Manninger, Martin ; Scherr, Daniel</creator><creatorcontrib>von Lewinski, Dirk ; Tripolt, Norbert J ; Sourij, Harald ; Pferschy, Peter N ; Oulhaj, Abderrahim ; Alber, Hannes ; Gwechenberger, Marianne ; Martinek, Martin ; Seidl, Sebastian ; Moertl, Deddo ; Nürnberg, Michael ; Roithinger, Franz Xaver ; Steinwender, Clemens ; Stühlinger, Markus ; Zirlik, Andreas ; Benedikt, Martin ; Kolesnik, Ewald ; Wallner, Markus ; Rohrer, Ursula ; Manninger, Martin ; Scherr, Daniel ; ERASe study group</creatorcontrib><description>Sodium glucose cotransporter 2 (SGLT2) have proven profound positive effects in heart failure with reduced ejection fraction (HFrEF). These effects are independent from the presence of diabetes. Metabolic effects, antiinflammatory, and antifibrotic properties are discussed as underlying mechanisms. Despite a strong correlation of ventricular arrhythmias with HFrEF, the impact of ertugliflozin on the ventricular arrhythmic burden has not been investigated, yet. Therefore, the Ertugliflozin to Reduce Arrhythmic burden in ICD ± CRT patientS (ERASe) trial was designed to investigate the efficacy and safety of ertugliflozin in patients with reduced and midrange ejection fraction (EF) with or without diabetes.
Within a multicentre, national, randomized, double-blind, placebo-controlled, phase 3b trial we aim to enrol a total of 402 patients across Austria. Patients with reduced or midrange EF and ICD ± CRT therapy >3 months and previous ventricular tachycardia (at least 10 documented VT episodes within the last 12 months) are randomized in a 1:1 ratio to ertugliflozin (5 mg once daily orally administered) or matching placebo. The primary endpoint of the ERASe trial is to investigate the impact of ertugliflozin on total burden of ventricular arrhythmias. Further objectives will include number of therapeutic interventions of implanted devices, atrial fibrillation and heart failure biomarkers.
The ERASe trial will be the first trial to test ertugliflozin in heart failure patients with nonpreserved ejection fraction and ongoing ICD ± CRT therapy regardless of their diabetic status. The ERASe trial may therefore extend the concept of SGLT2 inhibition to improve cardiac remodelling, including reduced arrhythmic burden.
Trial registration Identifier EudraCT Nr. 2020-002581-14 / ClinicalTrials.gov Identifier: NCT04600921</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2022.01.008</identifier><identifier>PMID: 35045327</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Biomarkers ; Blood pressure ; Body mass index ; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use ; Cardiac arrhythmia ; Congestive heart failure ; Defibrillators, Implantable ; Diabetes ; Diabetes mellitus ; Documentation ; Double-Blind Method ; Drug dosages ; Ejection fraction ; Ethics ; Fibrillation ; Glucose ; Health informatics ; Heart failure ; Heart Failure - drug therapy ; Heart Failure - therapy ; Humans ; Hypotheses ; Na+/glucose cotransporter ; Oral administration ; Patients ; Placebos ; Stroke Volume - physiology ; Tachycardia ; Telemedicine ; Therapeutic applications ; Treatment Outcome ; Ventricle ; Ventricular Function, Left - physiology</subject><ispartof>The American heart journal, 2022-04, Vol.246, p.152-160</ispartof><rights>2022 The Authors</rights><rights>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</rights><rights>2022. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-4d71510bb8710f069dc3a061b2e12540563981b81e6860c9297b90a2fe6956323</citedby><cites>FETCH-LOGICAL-c424t-4d71510bb8710f069dc3a061b2e12540563981b81e6860c9297b90a2fe6956323</cites><orcidid>0000-0002-7566-2047 ; 0000-0001-6290-3297 ; 0000-0002-8895-8488 ; 0000-0002-9349-8068 ; 0000-0002-3066-8947 ; 0000-0002-0545-4373 ; 0000-0002-5330-904X ; 0000-0003-3510-9594</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35045327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>von Lewinski, Dirk</creatorcontrib><creatorcontrib>Tripolt, Norbert J</creatorcontrib><creatorcontrib>Sourij, Harald</creatorcontrib><creatorcontrib>Pferschy, Peter N</creatorcontrib><creatorcontrib>Oulhaj, Abderrahim</creatorcontrib><creatorcontrib>Alber, Hannes</creatorcontrib><creatorcontrib>Gwechenberger, Marianne</creatorcontrib><creatorcontrib>Martinek, Martin</creatorcontrib><creatorcontrib>Seidl, Sebastian</creatorcontrib><creatorcontrib>Moertl, Deddo</creatorcontrib><creatorcontrib>Nürnberg, Michael</creatorcontrib><creatorcontrib>Roithinger, Franz Xaver</creatorcontrib><creatorcontrib>Steinwender, Clemens</creatorcontrib><creatorcontrib>Stühlinger, Markus</creatorcontrib><creatorcontrib>Zirlik, Andreas</creatorcontrib><creatorcontrib>Benedikt, Martin</creatorcontrib><creatorcontrib>Kolesnik, Ewald</creatorcontrib><creatorcontrib>Wallner, Markus</creatorcontrib><creatorcontrib>Rohrer, Ursula</creatorcontrib><creatorcontrib>Manninger, Martin</creatorcontrib><creatorcontrib>Scherr, Daniel</creatorcontrib><creatorcontrib>ERASe study group</creatorcontrib><title>Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Sodium glucose cotransporter 2 (SGLT2) have proven profound positive effects in heart failure with reduced ejection fraction (HFrEF). These effects are independent from the presence of diabetes. Metabolic effects, antiinflammatory, and antifibrotic properties are discussed as underlying mechanisms. Despite a strong correlation of ventricular arrhythmias with HFrEF, the impact of ertugliflozin on the ventricular arrhythmic burden has not been investigated, yet. Therefore, the Ertugliflozin to Reduce Arrhythmic burden in ICD ± CRT patientS (ERASe) trial was designed to investigate the efficacy and safety of ertugliflozin in patients with reduced and midrange ejection fraction (EF) with or without diabetes.
Within a multicentre, national, randomized, double-blind, placebo-controlled, phase 3b trial we aim to enrol a total of 402 patients across Austria. Patients with reduced or midrange EF and ICD ± CRT therapy >3 months and previous ventricular tachycardia (at least 10 documented VT episodes within the last 12 months) are randomized in a 1:1 ratio to ertugliflozin (5 mg once daily orally administered) or matching placebo. The primary endpoint of the ERASe trial is to investigate the impact of ertugliflozin on total burden of ventricular arrhythmias. Further objectives will include number of therapeutic interventions of implanted devices, atrial fibrillation and heart failure biomarkers.
The ERASe trial will be the first trial to test ertugliflozin in heart failure patients with nonpreserved ejection fraction and ongoing ICD ± CRT therapy regardless of their diabetic status. The ERASe trial may therefore extend the concept of SGLT2 inhibition to improve cardiac remodelling, including reduced arrhythmic burden.
Trial registration Identifier EudraCT Nr. 2020-002581-14 / ClinicalTrials.gov Identifier: NCT04600921</description><subject>Biomarkers</subject><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Bridged Bicyclo Compounds, Heterocyclic - therapeutic use</subject><subject>Cardiac arrhythmia</subject><subject>Congestive heart failure</subject><subject>Defibrillators, Implantable</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Documentation</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>Ejection fraction</subject><subject>Ethics</subject><subject>Fibrillation</subject><subject>Glucose</subject><subject>Health informatics</subject><subject>Heart failure</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - therapy</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Na+/glucose cotransporter</subject><subject>Oral administration</subject><subject>Patients</subject><subject>Placebos</subject><subject>Stroke Volume - physiology</subject><subject>Tachycardia</subject><subject>Telemedicine</subject><subject>Therapeutic applications</subject><subject>Treatment Outcome</subject><subject>Ventricle</subject><subject>Ventricular Function, Left - physiology</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMFu1DAQhi0EokvhAbggS1zKIenYTuxEnFbLApEqIZVythxnwjrKJovtVFpOfYe-IU-Cqy0cOHAajeb7f40-Ql4zyBkweTnkZjfkHDjPgeUA1ROyYlCrTKqieEpWAMCzSoE4Iy9CGNIqeSWfkzNRQlEKrlbEbH1cvo-uH-efbqJxph67xSI13u-Ocbd3lraL73Ci6dxsPlxurm_owUSHUwz0Ynu9_opZ9M6M7-ivu3u6poedCUibpqEhLt3xJXnWmzHgq8d5Tr593N5sPmdXXz41m_VVZgtexKzoFCsZtG2lGPQg684KA5K1HBkvCyilqCvWVgxlJcHWvFZtDYb3KOt04-KcXJx6D37-sWCIeu-CxXE0E85L0FxyJkslRZXQt_-gw7z4KX2XKCGFglIUiWInyvo5BI-9Pni3N_6oGegH_3rQyb9-8K-B6eQ_Zd48Ni_tHru_iT_CE_D-BGBScevQ62CTSoud82ij7mb3n_rfsaWSPg</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>von Lewinski, Dirk</creator><creator>Tripolt, Norbert J</creator><creator>Sourij, Harald</creator><creator>Pferschy, Peter N</creator><creator>Oulhaj, Abderrahim</creator><creator>Alber, Hannes</creator><creator>Gwechenberger, Marianne</creator><creator>Martinek, Martin</creator><creator>Seidl, Sebastian</creator><creator>Moertl, Deddo</creator><creator>Nürnberg, Michael</creator><creator>Roithinger, Franz Xaver</creator><creator>Steinwender, Clemens</creator><creator>Stühlinger, Markus</creator><creator>Zirlik, Andreas</creator><creator>Benedikt, Martin</creator><creator>Kolesnik, Ewald</creator><creator>Wallner, Markus</creator><creator>Rohrer, Ursula</creator><creator>Manninger, Martin</creator><creator>Scherr, Daniel</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7566-2047</orcidid><orcidid>https://orcid.org/0000-0001-6290-3297</orcidid><orcidid>https://orcid.org/0000-0002-8895-8488</orcidid><orcidid>https://orcid.org/0000-0002-9349-8068</orcidid><orcidid>https://orcid.org/0000-0002-3066-8947</orcidid><orcidid>https://orcid.org/0000-0002-0545-4373</orcidid><orcidid>https://orcid.org/0000-0002-5330-904X</orcidid><orcidid>https://orcid.org/0000-0003-3510-9594</orcidid></search><sort><creationdate>202204</creationdate><title>Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study</title><author>von Lewinski, Dirk ; Tripolt, Norbert J ; Sourij, Harald ; Pferschy, Peter N ; Oulhaj, Abderrahim ; Alber, Hannes ; Gwechenberger, Marianne ; Martinek, Martin ; Seidl, Sebastian ; Moertl, Deddo ; Nürnberg, Michael ; Roithinger, Franz Xaver ; Steinwender, Clemens ; Stühlinger, Markus ; Zirlik, Andreas ; Benedikt, Martin ; Kolesnik, Ewald ; Wallner, Markus ; Rohrer, Ursula ; Manninger, Martin ; Scherr, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-4d71510bb8710f069dc3a061b2e12540563981b81e6860c9297b90a2fe6956323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Bridged Bicyclo Compounds, Heterocyclic - therapeutic use</topic><topic>Cardiac arrhythmia</topic><topic>Congestive heart failure</topic><topic>Defibrillators, Implantable</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Documentation</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>Ejection fraction</topic><topic>Ethics</topic><topic>Fibrillation</topic><topic>Glucose</topic><topic>Health informatics</topic><topic>Heart failure</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - therapy</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Na+/glucose cotransporter</topic><topic>Oral administration</topic><topic>Patients</topic><topic>Placebos</topic><topic>Stroke Volume - physiology</topic><topic>Tachycardia</topic><topic>Telemedicine</topic><topic>Therapeutic applications</topic><topic>Treatment Outcome</topic><topic>Ventricle</topic><topic>Ventricular Function, Left - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>von Lewinski, Dirk</creatorcontrib><creatorcontrib>Tripolt, Norbert J</creatorcontrib><creatorcontrib>Sourij, Harald</creatorcontrib><creatorcontrib>Pferschy, Peter N</creatorcontrib><creatorcontrib>Oulhaj, Abderrahim</creatorcontrib><creatorcontrib>Alber, Hannes</creatorcontrib><creatorcontrib>Gwechenberger, Marianne</creatorcontrib><creatorcontrib>Martinek, Martin</creatorcontrib><creatorcontrib>Seidl, Sebastian</creatorcontrib><creatorcontrib>Moertl, Deddo</creatorcontrib><creatorcontrib>Nürnberg, Michael</creatorcontrib><creatorcontrib>Roithinger, Franz Xaver</creatorcontrib><creatorcontrib>Steinwender, Clemens</creatorcontrib><creatorcontrib>Stühlinger, Markus</creatorcontrib><creatorcontrib>Zirlik, Andreas</creatorcontrib><creatorcontrib>Benedikt, Martin</creatorcontrib><creatorcontrib>Kolesnik, Ewald</creatorcontrib><creatorcontrib>Wallner, Markus</creatorcontrib><creatorcontrib>Rohrer, Ursula</creatorcontrib><creatorcontrib>Manninger, Martin</creatorcontrib><creatorcontrib>Scherr, Daniel</creatorcontrib><creatorcontrib>ERASe study group</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>von Lewinski, Dirk</au><au>Tripolt, Norbert J</au><au>Sourij, Harald</au><au>Pferschy, Peter N</au><au>Oulhaj, Abderrahim</au><au>Alber, Hannes</au><au>Gwechenberger, Marianne</au><au>Martinek, Martin</au><au>Seidl, Sebastian</au><au>Moertl, Deddo</au><au>Nürnberg, Michael</au><au>Roithinger, Franz Xaver</au><au>Steinwender, Clemens</au><au>Stühlinger, Markus</au><au>Zirlik, Andreas</au><au>Benedikt, Martin</au><au>Kolesnik, Ewald</au><au>Wallner, Markus</au><au>Rohrer, Ursula</au><au>Manninger, Martin</au><au>Scherr, Daniel</au><aucorp>ERASe study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2022-04</date><risdate>2022</risdate><volume>246</volume><spage>152</spage><epage>160</epage><pages>152-160</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><abstract>Sodium glucose cotransporter 2 (SGLT2) have proven profound positive effects in heart failure with reduced ejection fraction (HFrEF). These effects are independent from the presence of diabetes. Metabolic effects, antiinflammatory, and antifibrotic properties are discussed as underlying mechanisms. Despite a strong correlation of ventricular arrhythmias with HFrEF, the impact of ertugliflozin on the ventricular arrhythmic burden has not been investigated, yet. Therefore, the Ertugliflozin to Reduce Arrhythmic burden in ICD ± CRT patientS (ERASe) trial was designed to investigate the efficacy and safety of ertugliflozin in patients with reduced and midrange ejection fraction (EF) with or without diabetes.
Within a multicentre, national, randomized, double-blind, placebo-controlled, phase 3b trial we aim to enrol a total of 402 patients across Austria. Patients with reduced or midrange EF and ICD ± CRT therapy >3 months and previous ventricular tachycardia (at least 10 documented VT episodes within the last 12 months) are randomized in a 1:1 ratio to ertugliflozin (5 mg once daily orally administered) or matching placebo. The primary endpoint of the ERASe trial is to investigate the impact of ertugliflozin on total burden of ventricular arrhythmias. Further objectives will include number of therapeutic interventions of implanted devices, atrial fibrillation and heart failure biomarkers.
The ERASe trial will be the first trial to test ertugliflozin in heart failure patients with nonpreserved ejection fraction and ongoing ICD ± CRT therapy regardless of their diabetic status. The ERASe trial may therefore extend the concept of SGLT2 inhibition to improve cardiac remodelling, including reduced arrhythmic burden.
Trial registration Identifier EudraCT Nr. 2020-002581-14 / ClinicalTrials.gov Identifier: NCT04600921</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35045327</pmid><doi>10.1016/j.ahj.2022.01.008</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7566-2047</orcidid><orcidid>https://orcid.org/0000-0001-6290-3297</orcidid><orcidid>https://orcid.org/0000-0002-8895-8488</orcidid><orcidid>https://orcid.org/0000-0002-9349-8068</orcidid><orcidid>https://orcid.org/0000-0002-3066-8947</orcidid><orcidid>https://orcid.org/0000-0002-0545-4373</orcidid><orcidid>https://orcid.org/0000-0002-5330-904X</orcidid><orcidid>https://orcid.org/0000-0003-3510-9594</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-8703 |
ispartof | The American heart journal, 2022-04, Vol.246, p.152-160 |
issn | 0002-8703 1097-6744 |
language | eng |
recordid | cdi_proquest_miscellaneous_2621657638 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Biomarkers Blood pressure Body mass index Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Cardiac arrhythmia Congestive heart failure Defibrillators, Implantable Diabetes Diabetes mellitus Documentation Double-Blind Method Drug dosages Ejection fraction Ethics Fibrillation Glucose Health informatics Heart failure Heart Failure - drug therapy Heart Failure - therapy Humans Hypotheses Na+/glucose cotransporter Oral administration Patients Placebos Stroke Volume - physiology Tachycardia Telemedicine Therapeutic applications Treatment Outcome Ventricle Ventricular Function, Left - physiology |
title | Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T07%3A59%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ertugliflozin%20to%20reduce%20arrhythmic%20burden%20in%20ICD/CRT%20patients%20(ERASe-trial)%20%E2%80%93%20A%20phase%20III%20study&rft.jtitle=The%20American%20heart%20journal&rft.au=von%20Lewinski,%20Dirk&rft.aucorp=ERASe%20study%20group&rft.date=2022-04&rft.volume=246&rft.spage=152&rft.epage=160&rft.pages=152-160&rft.issn=0002-8703&rft.eissn=1097-6744&rft_id=info:doi/10.1016/j.ahj.2022.01.008&rft_dat=%3Cproquest_cross%3E2621657638%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c424t-4d71510bb8710f069dc3a061b2e12540563981b81e6860c9297b90a2fe6956323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2636370534&rft_id=info:pmid/35045327&rfr_iscdi=true |